SINAPSE

CLINICAL STUDIES




Current Clinical Studies

Our ongoing/approved clinical studies are listed below. All studies have been approved by IRB, DSRB, or ethics boards based at the specified study sites.

Please contact our Clinical/Translational Team for more information. Please note that some trials are currently being conducted at international sites only. When local approval is obtained, the information on this page will be updated.

UPDATE (29.10.18): SINAPSE is currently preparing for the approvals of new human studies pertaining to neuroengineering and hematologic oncology. In addition, filings to expand existing studies to local sites have been made. Please check back for updates.



THERANOSTIC DEVICES

SINAPSE Investigators are currently conducting an interventional study pertaining to the use of a device to reduce chemotherapy-induced peripheral neuropathy (National University Hospital/NUH)

Active study: Clinicaltrials.gov: NCT03248193

Completed study: Clinicaltrials.gov: NCT03299582

ARTIFICIAL INTELLIGENCE: CURATE.AI

***UPDATE***

CURATE.AI: MM

We have received approval to conduct a prospective interventional study (NCT Phase 2/3-equivalent) pertaining to CURATE.AI-driven optimisation of multiple myeloma combination therapy. This is a N-of-1 clinical trial, with an estimated 20 subjects being recruited. This study will take place at National University Hospital (NUH)/National University Cancer Institute (NCIS). Interested parties should contact Mr. Theodore Kee (bietwk AT nus.edu.sg). More information can also be found at: Clinicaltrials.gov: NCT03759093.

CURATE.AI: GC

We have received approval to conduct a prospective expanded access interventional study pertaining to CURATE.AI-driven optimisation of gastric cancer combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients (In collaboration with Tan Tock Seng Hospital). Interested parties should contact Mr. Theodore Kee (bietwk AT nus.edu.sg).

CURATE.AI: MCRPC

We are currently conducting a prospective, first-in-human interventional study pertaining to CURATE.AI-driven optimisation of solid tumor combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients.

Note: This patient provided written informed consent to participate in a nonrandomized, open label, phase 1b/2a clinical trial (ClinicalTrials.gov: NCT02711956, US site).

Results for this study are pending. 

 

CURATE.AI: LT

N.1 Labs is currently conducting a prospective, expanded access first-in-human interventional study pertaining to CURATE.AI-driven optimisation of solid tumor combination therapy (metastatic/advanced). This is a N-of-1 clinical trial and is not currently recruiting additional patients (Taiwan site).

 

CURATE.AI: TM-L

N:1 Labs is currently conducting a prospective interventional study pertaining to CURATE.AI-driven optimisation of post-transplant immunosuppression. This is a N-of-1 clinical trial and patient recruitment is pending (Clinicaltrials.gov: NCT03527238, US site)

Results from the first-in-human study can be found in Science Translational Medicine, 333ra49, 2016 http://stm.sciencemag.org/content/8/333/333ra49 


N-of-1 Multitasking Training

N-of-1 Training Trajectories

SINAPSE announces the registration of a new N-of-1 interventional human study on multitasking training (Clinicaltrials.gov: NCT03832101; PI: Dr. Christopher Asplund). The study estimates the enrollment of up to 100 subjects (Clinicaltrials.gov: NCT03832101, NUS site.)

NANOMEDICINE

NDGP (Nano 1)

We have received approval to initiate clinical studies to validate Nanodiamond-Gutta Percha (NDGP) as a non-surgical root canal biomaterial (Clinicaltrials.gov: NCT02698163, US site).

Results from the first-in-human study can be found in PNAS, E9445, 2017 http://www.pnas.org/content/114/45/E9445

GPx (Nano 2)

We have received approval to initiate clinical studies to validate a therapeutic-Nanodiamond-GP (GPx) device (Clinicaltrials.gov: NCT03376984, US site).